HK Stock Market Move | BYD COMPANY (01211) is now up more than 5%. BYD Company Limited has started pre-sales at the Beijing Auto Show, with over 30,000 orders in the first 24 hours.
BYD Co., Ltd. (01211) is now up more than 5%, as of the press release, up 4.15%, at 105.4 Hong Kong dollars, with a turnover of 1.839 billion Hong Kong dollars.
BYD COMPANY (01211) is now up over 5%, as of the time of drafting, rose by 4.15%, to 105.4 Hong Kong dollars, with a turnover of 18.39 billion Hong Kong dollars.
On the news front, on April 24th, the 2026 Beijing International Auto Show opened. BYD Company Limited's new full-size flagship SUV, the Tang EV, officially began global pre-sales under the Wang Dynasty Network, with a pre-sale price of 250,000-320,000 yuan. Lu Tian, General Manager of the Sales Division of BYD Company Limited's Wang Dynasty Network, announced that the pre-sales of BYD Company Limited's Tang surpassed 30,000 units within 24 hours.
Guotai Haitong pointed out that BYD Company Limited showcased its electric product matrix covering multiple brands and categories, as well as its latest technological achievements, at this auto show, further strengthening its strategic layout in the high-end, intelligent, and market segmentation fields. The bank believes that although the overall passenger car market in China is under pressure, car companies with strong consumer demand grasp, high cost control levels, and good model cycle rhythm still have growth opportunities in 2026.
Related Articles

STANCHART (02888) will distribute a final dividend of HK$3.83746 per share on May 14th.

IMPRO PRECISION (01286) achieved a total revenue of HK$1.4276 billion in the first quarter, a year-on-year increase of 22.5%.

SSY Group (02005) obtained the drug production registration approval from the National Medical Products Administration for injectable Diltiazem Hydrochloride (10mg).
STANCHART (02888) will distribute a final dividend of HK$3.83746 per share on May 14th.

IMPRO PRECISION (01286) achieved a total revenue of HK$1.4276 billion in the first quarter, a year-on-year increase of 22.5%.

SSY Group (02005) obtained the drug production registration approval from the National Medical Products Administration for injectable Diltiazem Hydrochloride (10mg).






